225 related articles for article (PubMed ID: 31038062)
1. Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury.
Noce A; Marrone G; Rovella V; Busca A; Gola C; Ferrannini M; Di Daniele N
Curr Pharm Biotechnol; 2019; 20(5):366-375. PubMed ID: 31038062
[TBL] [Abstract][Full Text] [Related]
2. [Fenoldopam: potential clinical applications in heart surgery].
Shorten GD
Rev Esp Anestesiol Reanim; 2001 Dec; 48(10):487-91. PubMed ID: 11792308
[TBL] [Abstract][Full Text] [Related]
3. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
Tumlin JA; Finkel KW; Murray PT; Samuels J; Cotsonis G; Shaw AD
Am J Kidney Dis; 2005 Jul; 46(1):26-34. PubMed ID: 15983954
[TBL] [Abstract][Full Text] [Related]
4. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
[TBL] [Abstract][Full Text] [Related]
5. Effect of fenoldopam mesylate in critically ill patients at risk for acute renal failure is dose dependent.
Samuels J; Finkel K; Gubert M; Johnson T; Shaw A
Ren Fail; 2005; 27(1):101-5. PubMed ID: 15717642
[TBL] [Abstract][Full Text] [Related]
6. Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke.
Segev G; Bruchim Y; Berl N; Cohen A; Aroch I
J Vet Intern Med; 2018 May; 32(3):1109-1115. PubMed ID: 29575360
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
[TBL] [Abstract][Full Text] [Related]
8. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
Tumlin JA; Wang A; Murray PT; Mathur VS
Am Heart J; 2002 May; 143(5):894-903. PubMed ID: 12040355
[TBL] [Abstract][Full Text] [Related]
9. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.
Landoni G; Biondi-Zoccai GG; Tumlin JA; Bove T; De Luca M; Calabrò MG; Ranucci M; Zangrillo A
Am J Kidney Dis; 2007 Jan; 49(1):56-68. PubMed ID: 17185146
[TBL] [Abstract][Full Text] [Related]
10. Preventing contrast-induced nephropathy with fenoldopam.
Hunter DW; Chamsuddin A; Bjarnason H; Kowalik K
Tech Vasc Interv Radiol; 2001 Mar; 4(1):53-6. PubMed ID: 11981789
[TBL] [Abstract][Full Text] [Related]
11. Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
Asif A; Epstein DL; Epstein M
J Clin Pharmacol; 2004 Dec; 44(12):1342-51. PubMed ID: 15545304
[TBL] [Abstract][Full Text] [Related]
12. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
Chamsuddin AA; Kowalik KJ; Bjarnason H; Dietz CA; Rosenberg MS; Gomes MD; McDermott CM; Hunter DW
AJR Am J Roentgenol; 2002 Sep; 179(3):591-6. PubMed ID: 12185025
[TBL] [Abstract][Full Text] [Related]
13. Fenoldopam for acute kidney injury in children.
Knoderer CA; Leiser JD; Nailescu C; Turrentine MW; Andreoli SP
Pediatr Nephrol; 2008 Mar; 23(3):495-8. PubMed ID: 18000686
[TBL] [Abstract][Full Text] [Related]
14. Dopamine "renal dose" versus fenoldopam mesylate to prevent ischemia-reperfusion injury in renal transplantation.
Fontana I; Germi MR; Beatini M; Fontana S; Bertocchi M; Porcile E; Saltalamacchia L; Ornis S; Ghinolfi D; Bonifazio L; Valente U
Transplant Proc; 2005; 37(6):2474-5. PubMed ID: 16182714
[TBL] [Abstract][Full Text] [Related]
15. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
[TBL] [Abstract][Full Text] [Related]
16. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
Kini AA; Sharma SK
Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
Madyoon H
Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365
[TBL] [Abstract][Full Text] [Related]
18. Potential of dopamine A-1 agonists in the management of acute renal failure.
Singer I; Epstein M
Am J Kidney Dis; 1998 May; 31(5):743-55. PubMed ID: 9590183
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.
Morelli A; Ricci Z; Bellomo R; Ronco C; Rocco M; Conti G; De Gaetano A; Picchini U; Orecchioni A; Portieri M; Coluzzi F; Porzi P; Serio P; Bruno A; Pietropaoli P
Crit Care Med; 2005 Nov; 33(11):2451-6. PubMed ID: 16276165
[TBL] [Abstract][Full Text] [Related]
20. Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis.
Gillies MA; Kakar V; Parker RJ; Honoré PM; Ostermann M
Crit Care; 2015 Dec; 19():449. PubMed ID: 26703329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
